J. Goldman & Co LP Purchases 3,190 Shares of Waters Corporation $WAT

J. Goldman & Co LP grew its holdings in shares of Waters Corporation (NYSE:WAT) by 24.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,483 shares of the medical instruments supplier’s stock after acquiring an additional 3,190 shares during the quarter. J. Goldman & Co LP’s holdings in Waters were worth $6,182,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in WAT. Ancora Advisors LLC boosted its stake in shares of Waters by 82.1% in the 2nd quarter. Ancora Advisors LLC now owns 16,543 shares of the medical instruments supplier’s stock valued at $6,204,000 after purchasing an additional 7,457 shares in the last quarter. Canada Pension Plan Investment Board raised its position in Waters by 2,711.2% in the 2nd quarter. Canada Pension Plan Investment Board now owns 162,120 shares of the medical instruments supplier’s stock worth $60,801,000 after purchasing an additional 156,353 shares during the period. Parkman Healthcare Partners LLC raised its position in Waters by 14.2% in the 2nd quarter. Parkman Healthcare Partners LLC now owns 30,206 shares of the medical instruments supplier’s stock worth $11,328,000 after purchasing an additional 3,759 shares during the period. Legal & General Group Plc lifted its stake in Waters by 0.8% in the second quarter. Legal & General Group Plc now owns 690,148 shares of the medical instruments supplier’s stock worth $258,833,000 after purchasing an additional 5,335 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in Waters by 22.9% in the second quarter. Jones Financial Companies Lllp now owns 290,936 shares of the medical instruments supplier’s stock worth $108,930,000 after purchasing an additional 54,144 shares during the last quarter. 94.01% of the stock is currently owned by institutional investors.

Waters Stock Performance

Waters stock opened at $414.41 on Wednesday. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32. The firm has a market cap of $40.72 billion, a P/E ratio of 103.34, a P/E/G ratio of 2.39 and a beta of 1.19. The firm has a 50-day moving average of $383.92 and a 200-day moving average of $347.45. Waters Corporation has a 1-year low of $282.77 and a 1-year high of $421.74.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, beating the consensus estimate of $3.01 by $0.04. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.62 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. The firm’s revenue for the quarter was up 113.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.95 earnings per share. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Sell-side analysts expect that Waters Corporation will post 14.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Bank of America upped their price target on shares of Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday, June 2nd. Piper Sandler started coverage on Waters in a research note on Thursday, June 11th. They issued a “neutral” rating and a $400.00 target price for the company. TD Cowen upgraded Waters from a “hold” rating to a “buy” rating and increased their target price for the company from $408.00 to $475.00 in a report on Wednesday, August 5th. Morgan Stanley set a $430.00 price target on Waters in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada lifted their price target on Waters from $435.00 to $475.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $420.35.

Insider Buying and Selling

In other Waters news, Director Christopher A. Kuebler sold 3,626 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the sale, the director directly owned 17,808 shares in the company, valued at $7,086,515.52. This trade represents a 16.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is owned by insiders.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.